Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.

The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca's ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn't report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.